Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)
Close on Nov 18, 2026Market cap $6.09BP/E –Yield –
Arrowhead Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Arrowhead Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$226.44M. For fiscal 2025 it was $98.35M. The highest annual figure on record is $98.35M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $98.35M | – |
| FY2024 | Sep 30, 2024 | -$601.08M | – |
| FY2023 | Sep 30, 2023 | -$205.00M | – |
| FY2022 | Sep 30, 2022 | -$178.51M | – |
| FY2021 | Sep 30, 2021 | -$149.04M | – |
| FY2020 | Sep 30, 2020 | -$93.16M | -252.2% |
| FY2019 | Sep 30, 2019 | $61.19M | – |
| FY2018 | Sep 30, 2018 | -$55.94M | – |
| FY2017 | Sep 30, 2017 | -$37.00M | – |
| FY2016 | Sep 30, 2016 | -$81.74M | – |
| FY2015 | Sep 30, 2015 | -$95.97M | – |
| FY2014 | Sep 30, 2014 | -$53.28M | – |
| FY2013 | Sep 30, 2013 | -$24.59M | – |
| FY2012 | Sep 30, 2012 | -$21.09M | – |
| FY2011 | Sep 30, 2011 | -$9.83M | – |
| FY2010 | Sep 30, 2010 | -$5.83M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$170.09M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$141.26M | -137.1% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $40.81M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $44.11M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$165.55M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $381.20M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$161.41M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$162.20M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$176.14M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$126.19M | -362.0% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$136.55M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$108.33M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$102.70M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $48.17M | +15.9% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$42.13M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$83.83M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$72.91M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $41.55M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$63.32M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$64.88M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$31.87M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$28.23M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$24.05M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$50.12M | -620.0% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$15.95M | -185.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$22.24M | -201.0% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$4.85M | -144.3% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $9.64M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $18.60M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $22.01M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $10.95M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$11.17M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$15.92M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$15.03M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$13.81M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$10.25M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$5.71M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$6.13M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$14.90M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$21.80M | – |
See a number that looks wrong?